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Abstract
Background/Aim. The aim of this study was to apply com-
puter-assisted methodology in assessment of Ki-67 positivity
in “adenoma-like” dysplasia associated lesions or masses
(DALMs), and carcinoma in ulcerative colitis (UC), and to
determine a new approach to grading of Ki-67 staining inten-
sity.  Methods. Immunohistochemical slides were quantita-
tively analyzed for estimation of proportion and intensity of
Ki-67 positive-stained cells in a total of 50 “adenoma-like”
DALMs (27 with low-grade dysplasia and 23 with high-grade
dysplasia), and 17 adenocarcinomas associated with UC. The
four grades of immunohistochemical staining intensity were
established by an automated classification of nuclear optical
densities. Results. The Ki-67 labeling index (LI) in low-grade
dysplasia was significantly lower than in high-grade dysplasia,
and carcinoma (p < 0.001). The Ki-67 LI of carcinomas was
not significantly different from the value obtained in high-
grade dysplasia (p > 0.05), however having the difference in
percentage values of the moderate stained nuclei (p < 0.05).
The overall average values of chromogene nuclear optical
density, showed statistically significant differences between
DALMs and carcinoma (p < 0.05), although not between
normal mucosa and low-grade dysplasia (p > 0.05). Conclu-
sion.  The obtained results imply, according to the overall
percentage of labeled nuclei, that high-grade dysplasia is very
close to carcinoma, while there is the difference in the per-
centage of moderately stained nuclei. We showed that Ki-67
positivity have a different internal distribution which could be
useful in analysing these lesions. These findings also, indicate
the important biological differences between low-grade dys-
plasia and carcinoma in UC, and a low proliferative potential
of the former. Automated image analysis permits an objective
estimation of Ki-67 immunohistochemical staining in UC-
associated dysplasia and carcinoma.
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Apstrakt
Uvod/Cilj. Cilj ovog rada bio je primena kompjuterske
metodologije za procenu pozitivnosti Ki-67 antigena kod
„adenomu sličnih“ i sa displazijom udruženih lezija ili masa
(dysplasia associated lesions or masses - DALMs) i karcinoma kod
ulceroznog kolitisa (UK) i da utvrdi novi pristup stepenova-
nju intenziteta bojenja Ki-67. Metode. Imunohistohemijski
preparati kvantitativno su analizirani da bi se procenio pro-
cenat i intenzitet Ki-67 pozitivno obojenih ćelija kod ukup-
no 50 „adenomu sličnih“ DALMs (27 sa displazijom niskog
stepena i 23 sa displazijom visokog stepena) i 17 adenokar-
cinoma povezanih sa UK. Na osnovu automatske klasifika-
cije optičkih gustina jedara, određena su četiri stepena inten-
ziteta imunohistohemijskog bojenja. Rezultati.  Indeks
obeležavanja Ki-67 (labeling index – LI) kod displazije niskog
stepena bio je značajno niži nego kod displazije visokog ste-
pena i karcinoma (p < 0,001). Kod karcinoma Ki-67 LI nije
se značajno razlikovao od vrednosti dobijene kod displazije
visokog stepena (p > 0,05), međutim, postoje razlike u pro-
centnim vrednostima kod umereno obojenih jedara (p  <
0,05). Ukupne prosečne vrednosti hromogene optičke gus-
tine jedara pokazale su statistički značajne razlike između
DALMs i karcinoma (p < 0,05), mada ne i između normalne
mukoze i displazije niskog stepena (p > 0,05). Zaključak.
Dobijeni rezultati, prema ukupnom procentu obeleženih je-
dara, ukazuju na veliku sličnost između displazije visokog
stepena i karcinoma, ali i da postoje razlike u procentu ume-
reno obojenih jedara. Pokazali smo da Ki-67 pozitivnost
ima različitu unutrašnju distribuciju koja može da bude kori-
sna u analizi ovih lezija. Ovi nalazi, takođe, ukazuju na važ-
ne biološke razlike između displazije niskog stepena i karci-
noma kod UK i niski proliferativni potencijal displazije nis-
kog stepena. Automatska analiza slike omogućuje objektiv-
nu procenu Ki-67 imunohistohemijskog bojenja kod displa-
zija i karcinoma povezanih sa UK.
Ključne reči:
kolitis, ulcerativni; polipi; karcinomi; kompjuteri; imu-
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Introduction
Patients with long-standing extensive ulcerative colitis
(UC) are at increased risk for the development of colorectal
carcinoma
 1–4. Widely accepted classical risk factors are long
disease duration and involvement of the entire colon
 1. This
increased risk begins approximately 7–10 years following
disease onset, and increases at a rate of 0.5–1.0% per year
 5.
The risk of colorectal cancer (CRC) is much greater in the
UC patients who also have primary sclerosing cholangitis,
and family history of colon cancer
 6, 7. Most studies reported
that epithelial dysplasia is the most important marker of an
increased risk of malignancy in patients with UC. Dysplasia
in ulcerative colitis may be classified as flat and elevated
(dysplasia associated lesion or mass [DALMs])
 3. They are
frequently associated with a high proportion of colorectal
carcinoma and are an indication for colectomy
 3, 4. However,
recent data suggest that DALMs are a heterogeneus popula-
tion of lesions, and that not all subtypes carry a high risk of
malignancy
 8, 9.
Dysplasia associated lesion or masses are subdivided
into “non-adenoma-like” and “adenoma-like” lesions based
on their endoscopic appearance
 10–12.
“Non-adenoma-like” DALMs were defined as elevated
dysplastic lesions that were irregular, broad based, or stric-
tured lesion. Patients with a “non-adenoma-like” DALMs
(regardless of the dysplasia grade), should be treated with
colectomy because of the high probability of adenocarci-
noma
 11.
“Adenoma-like” DALM was definited as a discrete,
well-definited, sessile or peduncular polyp in which endo-
scopic and histopathological distinction from a sporadic ade-
noma was not possible
 10. Recent studies have highlighted the
possibility of performing a colonoscopic polypectomy for
patients with “adenoma-like” DALM
 12–14.
Dysplastic epithelium in UC is subdivided into low-
grade and high-grade depending on the severity of the atypia
2. There is a general consensus that the low-grade dysplasia
warrants, at least requires, long-term colonoscopic surveil-
lance, whereas the emergency of high-grade dysplasia is best
managed by colectomy to eliminate potential strong risk of
cancer development 
2.
Although hematoxylin and eosin (H&E) histopathology
is still the “gold standard” for the grading of dysplasia and its
distinction from regenerative epithelial changes, the previous
study has revealed variations in the interobserver agreement
in diagnosis and dysplasia grading in UC. Under the circum-
stances, there is the necessity for a precise estimation of cell
proliferation deregulation in dysplasias, especially for objec-
tivization of diagnostic processes, and finally for establishing
new promising therapeutic approaches. One of the most reli-
able markers for cellular proliferation is monoclonal anti-
body Ki-67 (MIB-1) 
15.
The Ki-67, a large nuclear protein, probably plays an
important role in the regulation of cell proliferation. Antigen
is Ki-67 expressed during all active phases of the cell cycle
(G1, S, G2, and M, grade, stage and metastasis), but not in the
G0 phase. The expression increases with the cell progression
rising during the second half of the S-phase and reaching a
peak in the G2 and M-phase 
15. Immunohistochemical esti-
mation of Ki-67 was previously used in dysplastic lesion as-
sociated with UC 
16–18. These reports determined the percent-
age, and/or location of Ki-67 staining, however none of them
presented exact quantification of the targeted protein staining
intensity.
In recent years, many efforts have been done to re-
place conventional estimation of immunohistochemically
evidenced proteins in tumor nuclei. These attempts were
based on separation and photometrical analysis of specific
color of immunohistochemical chromogene, especially,
diaminobenzidine (DAB) 
19-21. The problem of quantitative
immunohistochemistry is accurate separation of chromo-
gene stain from color of colocalized counterstain. The
breakthrough, in this field was made by Ruifrok and
Johnston, which proposed the color deconvolution algo-
rithm, with which is possible to separate immunostained
and counterstained components, even in cases of overlap-
ping spectral absorption spectra, as well as colocalisation
 22.
The major obstacle in immunoreactivity estimation is de-
termining, as previously reported by Walker 
23, “what is
positive” in tissue sample, in other words which level of
visible chromogene is appropriate to determine if the target
structure is positive or not.
The aim of this study, therefore, was to apply computer-
assisted methodology in assessment of Ki-67 positivity in
“adenoma-like” DALMs and carcinoma in chronic UC, as
well as to determine a new approach to scoring their patterns.
Methods
The formalin-fixed paraffin-embedded tissue specimens
from 50 polypectomy or colectomy resected “adenoma-like”
DALMs (47 patients) and 17 resected adenocarcinomas (17
patients) were selected from the files of the Institute of Pa-
thology, during the period from January 2000 to December
2006. All the patients had a history of long-standing (> 10
years) subtotal and total UC and their lesions had arisen from
UC affected colonic mucosa.
The patients with DALM consisted of 31 males and 16
females (mean age: 52 years, range: 38–75 years). The carci-
noma study group consisted of 12 males and 5 females with
the mean age of 64 years (range: 45–79 years).
The histological criteria for UC-associated lesions, de-
scribed by Riddell et al, 
2 were applied. Of the 50 “adenoma-
like” DALMs evaluated, low-grade dysplasia (LGD) was in
27, and high-grade dysplasia (HGD) in 23 specimens. All
tissue samples were independently evaluated by the two pa-
thologists. When a discrepancy in dysplasia grading occured
between the two observers, the lower of the values was used
as the final one.
For the positive controls, 30 specimens of normal co-
lonic mucosa from 23 surgically resected samples, suffi-
ciently distant from sporadic CRC, were obtained.
Multiple serial 4 μm tissue section were prepared, one
of which was stained with H&E for histological evaluation,
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Immunohistochemistry for Ki-67
The slides were deparaffinized and endogenous peroxi-
dase activity was blocked by incubation in 3% hydrogen
peroxide in phosphate-buffered saline (PBS) for 30 minutes
at room temperature and washed in PBS for 5 minutes. Anti-
gen retrieval was perfomed by heating the sections for 10
minutes at 100 °C in 10 mM citrate buffer (pH 6.0), and the
left to cool to room temperature for 20 minutes. The primary
antibody, anti-Ki-67 (MIB-1, Dako Corporation; Glostrub,
Denmark) was incubated with the sections at 1:100 dilution
for 18 hours at 4 °C. The section were thoroughly rinsed and
exposed to the secondary antibody (Dako) for 30 min at
room temperature. Staining was performed with the Labeled
Strept-Avidin Biotin (LSAB) method, using 3.3’–diamino-
benzidine as chromogen. The sections were counterstained
with 0.1% hematoxylin (Sigma), dehydrated, and mounted.
The negative controls were incubated in buffer without
a primary antibody.
Image acquisition and analysis
The microscopic slides of all the groups stained for MIB-
1 were examined on microscope Leica DMR (Leica Micro-
Systems, Reuil-Malmaison, France), at the overall magnifica-
tion of 200x. Bright field microscopic images (five the most
representative areas from each slide, containing at least 1 000
nuclei per case) were obtained under the same conditions (in-
tensity of light, aperture of condensor system), white-balanced
and captured as digital images (8-bit RGB color images, 2088
× 1552 pixels) using digital camera (Leica DC 300). The files
were saved as uncompressed TIFF format of the sizes about 9
MB. From each image, taking the whole glands in account,
more than 1000 nuclei per case were interactively selected
using Genius tablet (EasyPen, KYE Systems Corp.), and
Adobe Photoshop`s v. 7.0 function polygonal lasso (adding
new nuclei to multiple selection constantly holding shift key),
cut, pasted, and merged in new generated image with white
background (with the same pixel dimensions), which was
saved as a separate file. Separation of the image files into blue
(hematoxylin-image), and brown (DAB-image) was per-
formed using colour deconvolution plugin by Landini
 24, writ-
ten for image analysis software Scion Image v. 1.37a for Win-
dows (Scion Corporation, Frederick, MD, U.S.A.), while the
images with chromogene were only saved as separate files.
The Olympus MicroImage Software, v. 4.0 for Windows (Me-
dia Cybernetics, Silver Spring, MD, U.S.A) was used to de-
termine outlines of nuclei by applying histogram based tresh-
old on previously prepared, non-deconvoluted images with
white background, which were finally saved as separate file of
settings. Saved outlines were then applied on deconvoluted
images (with chromogene only), to calculate the percentage of
labeled nuclei, and mean optical density, per each analyzed
case. Optical density represented the strength of pixel’s brown
signal on images, and pixels which were stained blue prior to
deconvolution had the value of 0. The four grades of immuno-
histochemical staining intensity (0, 1+, 2+, and 3+) were es-
tablished by MicroImage`s autoclassification according to the
iteration of nuclear optical densities. Grade 0 was considered
immunohistochemically negative for Ki-67 staining, grade 1+
weak, 2+ moderate, and 3+ strong intensity.
Statistical analysis
Statistical evaluation was carried out with the software
SigmaStat for Windows v 3.0 (SPSS Inc, Chicago, IL, USA).
The differences between the groups and grades of the exam-
ined cases were assessed by Mann-Whitney test. A p-value <
0.05 was considered significant.
Results
The immunohistochemical patterns showed a great di-
versity in the crypts of the examined cases. In DALMs with
low-grade dysplasia, Ki-67 immunoreactivity was prominent
mainly in the expanded basal zone of the crypt (Figure 1),
and rarely evident in the surface epithelium. However, in
cases with high-grade dysplasia, Ki-67 was diffusely distrib-
uted throughout the crypts (Figure 2). In the normal colonic
mucosa, only the cells of the crypt base were labeled. Diffuse
Ki-67 immunoreactivity was observed in irregular, back to
back and markedly budded crypts of carcinomas (Figure 3).
Fig. 1 – Positive staining for Ki-67 is localized in the expanded
basal zone of the crypts in low-grade dysplasia (LSAB, 200 ×)
Fig. 2 – Ki-67 positive cells are present throughout the crypts in
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Fig. 3 – Diffuse Ki-67 immunoreactivity seen in
adenocarcinoma (LSAB, 200 ×)
The great heterogenecity of staining intensity with
MIB-1 was obvious in each of the examined groups. The
staining pattern of nuclei differed from the diffuse weak in-
tensity, moderate granular, to homogenous strong.
According to quantitative immunohistochemistry, the
percentage of Ki-67 negative nuclei was the highest in the
group of normal mucosa (76.86±4.99), and the lowest in group
of carcinomas (21.47±10.88). Weak (1+) positive cells showed
a statistically significant difference among normal colonic mu-
cosa and low-grade dysplasia (p < 0.001), and low-grade dys-
plasia and high-grade dysplasia (p < 0.05). However, the dif-
ferences between high-grade dysplasia and carcinoma were
not significant (p > 0.05). Moderate (2+) positive cells pre-
sented significant differences of labeling indices among all
groups, with the higher percentage of Ki-67 positive cells in
carcinomas (30.49±2.73). In (3+) strong positive cells no sig-
nificant differences were noted only between high-grade dys-
plasia and carcinoma (p > 0.05) (Table 1).
The differences in optical density values between nor-
mal mucosa and low-grade dysplasia in each intensity grade
were not found (p > 0.05). Optical density, raised with grade
of staining intensity, and showed the highest values in the
grade 3+ of carcinomas (0.208±0.007). Statistically signifi-
cant differences (p < 0.05; p < 0,001) were noticed between
low-grade dysplasia, high-grade dysplasia and carcinoma of
the grades 1+, 2+, and 3+ (Table 1).
As shown in Table 2, the overall percentage of Ki-67
positive cells was statistically different between examined
histology groups (p  < 0.001), except between high-grade
dysplasia and carcinoma (p > 0.05).
Table 1
Comparative survey of the labeled nuclei percentage, and optical density
according to different grades of Ki-67 staining intensity
Groups Grades of
Ki-67 intensity
Labeled nuclei
percentage Optical density
n mean ± SD p < mean ± SD p <
N 30 76.86±4.99 0.0±0.0
LGD 27 51.42±5.52 0.0±0.0
HGD 23 31.30±7.14 0.0±0.0
CRC
negative - 0
17  21.47±10.88
0.001
0.001
0.0±0.0
-
-
-
N 30 12.97±3.73 0.047±0.048
LGD 27 18.60±0.75 0.043±0.007
HGD 23 20.52±1.29 0.067±0.019
CRC
weak - 1+
17 24.81±5.56
0.001
0.05
0.076±0.049
0.05
0.05
N 30  5.48±2.02 0.082±0.079
LGD 27 14.65±2.16 0.098±0.002
HGD 23 28.95±4.78 0.123±0.004
CRC
moderate - 2+
17 30.49±2.73
0.001
0.001
0.05 0.166±0.009
0.001
0.05
N 30  4.69±2.30 0.124±0.085
LGD 27 15.34±3.44 0.153±0.012
HGD 23 19.23±3.20 0.174±0.017
CRC
strong - 3+
17 23.23±2.30
0.001
0.001
0.208±0.007
0.05
0.05
N – normal; LGD – low grade dysplasia; HGD – high grade dysplasia, CRC – colorectal cancer
Table 2
Overall percentage, and optical density of Ki-67 positive nuclei in relation to the groups
Groups Overall
percentage
Optical
density
n mean±SD p < mean±SD p <
N 30 23.15±4.99 0.0844±0.0757
LGD 27 48.58±5.52 0.0980±0.0471
HGD 23 68.70±7.14 0.1210±0.0460
CRC 17  78.53±10.88
0.001
0.001
0.1680±0.0336
0.05
0.05
N – normal; LGD – low grade dysplasia; HGD – high grade dysplasia; CRC – colorectal
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According to optical density of Ki-67 positive nuclei,
statistical analysis showed that histology groups differed sig-
nificantly (p < 0.05; p < 0.001), except for normal mucosa
and low-grade dysplasia (p > 0.05) (Table 2). The examples
of Ki-67 optical density in normal mucosa, in low- and high-
grade dysplasia and in carcinoma are shown in Table 2.
Discussion
It is postulated that UC cancer is derived presumably
from the fields of dysplastic precursor lesions. The concept
of DALM, one subtype of dysplasia in UC, was first given
by Blackstone et al. 
3 in 1981. Dysplasia associated lesion or
masses are frequently associated with UC cancer 
3-4. How-
ever, recent studies point out that not all subtypes (“ade-
noma-like DALMs”) are at high risk of carcinoma 
8, 9, 12–14.
Only a few reports have evaluated immunohistochemi-
cally Ki-67 protein in UC-associated dysplasia with the pur-
pose of determining characteristics of cell proliferation, and
its malignant potential 
16–18, 25–26. Noffsinger et al, 
16 eluci-
dated that in some dysplasias, and all carcinomas, Ki-67 is
diffusely distributed throughout the crypts, suggesting com-
plete deregulation of normal cell proliferation. Two other
studies used the MIB-1 antibody to detect the percentage Ki-
67 stained nuclei (labeling index, LI) in relation to the distri-
bution throughout the mucosal crypts in UC-associated dys-
plasia
 17, 18.
In this study, the percentage of Ki-67 positive cells
varied considerably among the studied groups. Statistically
significant differences in the percentage of Ki-67 positive
cells occurred among carcinoma, low-grade dysplasia, and
normal mucosa (p < 0.001). The percentage of Ki-67 positive
cells was significantly higher in high-grade than in low-grade
dysplasia and normal mucosa (p  < 0.001). Our results
showed a progressive increase in the Ki-67 LI in “adenoma-
like” DALMs in the order of normal mucosa, DALM with
low-grade dysplasia and DALM with high-grade dysplasia.
The interesting observation was that Ki-67 LI of carcinomas
was not significantly different from the value obtained for
DALMs with high-grade dysplasia (p > 0.05). The finding
related to overall percentage of positive cells is only partially
concordant with the previously published results, which were
based on a semiquantitative estimation of immunohistochemi-
cal labeling 
17, 18. Andersen et al, 
18 did not find significant dif-
ferences in the percentage of Ki-67 positive cells between low-
grade dysplasia and high-grade dysplasia, as well as high-
grade dysplasia and carcinoma, but they could show signifi-
cant differences between carcinoma and low-grade dysplasia.
However, Kullmann et al, 
17 found that Ki-67 LI is signifi-
cantly higher in high-grade dysplasia compared with low-
grade dysplasia. Routine estimation of immunohistochemical
staining intensity, especially for the purpose of scoring differ-
ent histopathological patterns, is substantially based on sub-
jective determination of an average presence of the visible
chromogene 
16–18, 25, 26. In fact, “positivity” of immunohisto-
chemically stained tissues is not a fully defined category, and
represents more than an average value of staining intensity 
23.
In our results, according to an overall percentage of labeled
nuclei, high-grade dysplasia is very close to carcinoma, how-
ever showing the difference in the percentage values of the
grades of moderate stained nuclei. We showed that Ki-67 im-
munohistochemical “positivity” have different internal distri-
bution which could be useful in analysing these lesions. One
of the interesting findings is that the overall average values of
optical density, showed no statistically significant differences
between the normal mucosa and low-grade dysplasia, as well
as in the different grades of staining intensity, which could be
a reflection of similar Ki-67 protein amounts, and lower pro-
liferative potential.
Conclusion
Our method for quantification of MIB-1 expression is
an eclectic solution based on earlier attempts to separate im-
munohistochemically labeled areas, separating colors, and
calculating their photometrical properties 
19–21, 24, 27. Moreo-
ver, we recommend a system capable to make a distinction
between the different proliferative properties of “adenoma-
like” DALM, and carcinoma in ulcerative colitis, minimizing
a subjective estimation of their patterns.
REFERENCES
1.  Lennard-Jones JE, Morson BC, Ritchie JK, Williams CB. Cancer
surveillance in ulcerative colitis. Experience over 15 years.
Lancet 1983; 2(8342): 149–52.
2.  Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio
CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease:
standardized classification with provisional clinical applica-
tions. Hum Pathol 1983; 14(11): 931–68.
3.  Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-
associated lesion or mass (DALM) detected by colonoscopy in
long-standing ulcerative colitis: an indication for colectomy.
Gastroenterology 1981; 80(2): 366–74.
4.  Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in
patients with inflammatory bowel disease: a population-based
study. Cancer 2001; 91(4): 854–62.
5.  Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterol-
ogy 1988; 94(4): 1089–91.
6.  Raj V, Lichtenstein DR. Hepatobiliary manifestations of in-
flammatory bowel disease. Gastroenterol Clin North Am 1999;
28(2): 491–513.
7.  Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg
R, et al. Family history as a risk factor for colorectal cancer in
inflammatory bowel disease. Gastroenterology 2001; 120(6):
1356–62.
8.  Odze RD. Adenomas and adenoma-like DALMs in chronic ul-
cerative colitis: a clinical, pathological, and molecular review.
Am J Gastroenterol 1999; 94(7): 1746–50.
9.  Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD. P53 and
beta catenin expression in chronic ulcerative colitis – associ-
ated polypoid dysplasia and sporadic adenomas: an immuno-
histochemical study. Am J Surg Pathol 1999; 23(8): 963–9.
10. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adeno-
mas in inflammatory bowel disease: a clinical, pathologic, andStrana 758 VOJNOSANITETSKI PREGLED Volumen 64, Broj 11
Živković V, et al. Vojnosanit Pregl 2007; 64(11): 753–758.
follow-up study of 89 polyps from 59 patients. Am J Surg
Pathol 1998; 22(3): 275–84.
11. Odze RD, Brown CA, Hartmann CJ, Noffsinger AE, Fogt F. Ge-
netic alterations in chronic ulcerative colitis-associated ade-
noma-like DALMs are similar to non-colitic sporadic adeno-
mas. Am J Surg Pathol 2000; 24(9): 1209–16.
12. Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-
up after polypectomy treatment for adenoma-like dysplastic le-
sions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;
2(7): 534–41.
13. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be ade-
quate treatment for adenoma-like dysplastic lesions in chronic
ulcerative colitis. Gastroenterology 1999; 117(6): 1288–94.
14. Rubin PH, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J,
et al. Colonoscopic polypectomy in chronic colitis: conserva-
tive management after endoscopic resection of dysplastic pol-
yps. Gastroenterology 1999; 117(6): 1295–300.
15. Scholzen T, Gerdes J. The Ki-67 protein: from the known and
the unknown. J Cell Physiol 2000; 182(3): 311–22.
16. Noffsinger AE, Miller MA, Cusi MV, Fenoglio-Preiser CM. The
pattern of cell proliferation in neoplastic and nonneoplastic le-
sions of ulcerative colitis. Cancer 1996; 78(11): 2307–12.
17. Kullmann F, Fadaie M, Gross V, Knuchel R, Bocker T, Steinbach P,
et al. Expression of proliferating cell nuclear antigen (PCNA)
and Ki-67 in dysplasia in inflammatory bowel disease. Eur J
Gastroenterol Hepatol 1996; 8(4): 371–9.
18. Andersen SN, Rognum TO, Bakka A, Clausen OP. Ki-67: a useful
marker for the evaluation of dysplasia in ulcerative colitis. Mol
Pathol 1998; 51(6): 327–32.
19. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM.
Application of photoshop-based image analysis to quantifica-
tion of hormone receptor expression in breast cancer. J Histo-
chem Cytochem 1997; 45(11): 1559–65.
20. Hasegawa T, Yamamoto S, Matsuno Y. Quantitative immunohis-
tochemical evaluation of MIB-1 labeling index in adult soft-
tissue sarcomas by computer-assisted image analysis. Pathol
Int 2002; 52(7): 433–7.
21. Kim YJ, Romeike BF, Uszkoreit J, Feiden W. Automated nuclear
segmentation in the determination of the Ki-67 labeling index
in meningiomas. Clin Neuropathol 2006; 25(2): 67–73.
22. Ruifrok AC, Johnston DA. Quantification of histochemical
staining by color deconvolution. Anal Quant Cytol Histol
2001; 23(4): 291–9.
23. Walker RA. Quantification of immunohistochemistry – issues
concerning methods, utility and semiquantitative assessment I.
Histopathology 2006; 49(4): 406–10.
24. Landini G. Quantitative analysis of the epithelial lining archi-
tecture in radicular cysts and odontogenic keratocysts. Head
Face Med 2006; 2: 4.
25. Wong NA, Mayer NJ, MacKell S, Gilmour HM, Harrison DJ. Im-
munohistochemical assessment of Ki67 and p53 expression
assists the diagnosis and grading of ulcerative colitis-related
dysplasia. Histopathology 2000; 37(2): 108–14.
26. Fogt F, Poremba C, Shibao K, Itoh H, Kohno K, Zimmerman RL,
et al. Expression of survivin, YB-1, and KI-67 in sporadic
adenomas and dysplasia-associated lesions or masses in ul-
cerative colitis. Appl Immunohistochem Mol Morphol 2001;
9(2): 143–9.
27. Taylor CR, Levenson RM. Quantification of immunohistochem-
istry – issues concerning methods, utility and semiquantitative
assessment II. Histopathology 2006; 49(4): 411–24.
The paper was received on August 1, 2007.